Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.
Saved in:
| Title: | Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study. |
|---|---|
| Authors: | Pasello G; Department of Surgery Oncology and Gastroenterology, University of Padova, Padua, Italy.; Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy., Proto C; Istituto Nazionale Tumori, Milan, Italy., Genova C; Ospedale Policlinico San Martino, Genoa, Italy., Pavan A; Department of Medical Oncology, AULSS 3 Serenissima, Ospedale dell'Angelo, Venezia, Italy., Roca E; Thoracic Oncology - Lung Unit, Pederzoli Hospital, Peschiera del Garda, Verona, Italy., Minuti G; Clinical Trials Unit - Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy., D'Aniello C; Unit of Oncology, A.O. dei Colli P.O. Monaldi, Naples, Italy., Giusti R; A.O.U. Sant'Andrea, Rome, Italy., Mariotti S; Policlinico Tor Vergata, Rome, Italy., Romano FJ; A.O.R.N. Cardarelli, Naples, Italy., Polo V; Oncology Unit, AULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy., Belluomini L; Section of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy., Baldini E; Ospedale San Luca, Lucca, Italy., Mazzoni F; Oncology Department, Careggi University Hospital, Florence, Italy., Bettini AC; ASST Papa Giovanni XXIII, Bergamo, Italy., Gristina V; Department of Precision Medicine in Medical, Surgical and Critical Care, AOUP Paolo Giaccone University Hospital, Palermo, Italy., Russo A; A.O. Papardo, Messina, Italy., Grossi F; Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy.; Medical Oncology Division, ASST Sette Laghi, Varese, Italy., Ogliari FR; Dept. Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.; Università Vita-Salute San Raffaele, Pesaro (PU), Milan, Italy., Gelsomino F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Chiari R; Ospedale San Salvatore - Muraglia, Pesaro (PU), Italy., Bria E; Fondazione Policlinico Universitario A. Gemelli, Rome, Italy., Fioroni I; Policlinico Universitario Campus Bio-Medico, Rome, Italy., Cortinovis D; SC Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.; Department of Medicine, University of Milano-Bicocca, Milan, Italy., Pizzutilo EG; ASST GOM Niguarda, Milan, Italy., Zanetti A; AstraZeneca Italy, Milan, Italy., Pasqualetti G; AstraZeneca Italy, Milan, Italy., Roncari B; IQVIA Solutions Italy SRL, Modena, Italy., Simoni L; IQVIA Solutions Italy SRL, Modena, Italy., Catino A; Thoracic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy. |
| Corporate Authors: | ELBA Study Group |
| Source: | Frontiers in oncology [Front Oncol] 2026 Feb 16; Vol. 16, pp. 1724019. Date of Electronic Publication: 2026 Feb 16 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1724019 |
